Of note, a subcluster of endometrioid endometrial carcinoma cases with a unique mutational profile (with mutations in PTEN/FGFR2/NRAS/CCND1/CYLC1 and no mutation in PIK3CA and none of type I endometrial carcinoma mutations) have a significantly better prognosis (p value: